Table 26 Concomitant medication of patients with atrial fibrillation using VKAs or OAC. (Continuation of Table 24)
| Â | Â | VKA | Dabigatran | Rivaroxaban | Apixaban |
|---|---|---|---|---|---|
ADP receptor antagonists | Paper | 10% | 8% | 10% | 11% |
| Â | UKW_11 | 4% | 8% | 3% | 4% |
| Â | UKW_16 | 5% | 10% | 11% | 3% |
ASS | Paper | 43% | 38% | 38% | 36% |
| Â | UKW_11 | 11% | 15% | 13% | 11% |
| Â | UKW_16 | 9% | 15% | 11% | 8% |
Non-steroidal antiinflammatory drugs | Paper | 15% | 15% | 14% | 14% |
| Â | UKW_11 | 6% | 5% | 5% | 3% |
| Â | UKW_16 | 8% | 9% | 8% | 5% |
Loop diuretics | Paper | 22% | 15% | 18% | 19% |
| Â | UKW_11 | 59% | 42% | 42% | 52% |
| Â | UKW_16 | 60% | 40% | 41% | 54% |
Beta-blockers | Paper | 45% | 38% | 39% | 37% |
| Â | UKW_11 | 77% | 76% | 77% | 78% |
| Â | UKW_16 | 77% | 72% | 75% | 76% |
Calcium channel blockers | Paper | 29% | 26% | 27% | 26% |
| Â | UKW_11 | 32% | 29% | 30% | 30% |
| Â | UKW_16 | 32% | 33% | 29% | 28% |
Renin-angiotensin system inhibitors | Paper | 43% | 42% | 41% | 43% |
| Â | UKW_11 | 46% | 40% | 38% | 42% |
| Â | UKW_16 | 39% | 42% | 35% | 38% |